FilingReader Intelligence

Aurobindo Pharma acquires Lannett Company for $250m

July 30, 2025 at 07:03 PM UTC•By FilingReader AI

Aurobindo Pharma announced the acquisition of Lannett Company LLC by its subsidiary Aurobindo Pharma USA Inc. for $250 million. The deal strengthens Aurobindo's US manufacturing and controlled substance portfolio.

The company also restructured its biosimilars business by transferring CuraTeQ Biologics shares between subsidiaries to streamline operations.

This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com

Primary Source Document

Intimation of entering into binding agreement for transfer of shares of Curateq Biologics s.r.o., by Helix Healthcare B.V to Curateq Biologics B.V., wholly owned subsidiaries of the CompanyJuly 30, 2025 at 11:59 AM UTC

Supplementary Source Documents

Intimation of acquisition of Lannett Company LLC, USA by Aurobindo Pharma USA Inc, a wholly owned subsidiary of the CompanyJuly 30, 2025 at 02:11 PM UTC

Aurobindo Pharma

BSE:AUROPHARMA•Bombay Stock Exchange

RSS feed for Aurobindo Pharma

News Alerts

Get instant email alerts when Aurobindo Pharma publishes news

Free account required • Unsubscribe anytime

Browse RSS Feeds

Filing Activity Timeline

View Complete Filing History →